ECM
ADAP

Endurant Capital Management’s Adaptimmune Therapeutics ADAP Stock Holding History

Endurant Capital Management’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-311,944
Closed -$243K – 28
2023
Q3 		$243K Sell
311,944
-509,094
-62% -$427K 0.22% 43
2023
Q2 		$759K Sell
821,038
-839,797
-51% -$1M 0.66% 27
2023
Q1 		$1.81M Sell
1,660,835
-72,401
-4% -$112K 0.93% 28
2022
Q4 		$2.53M Sell
1,733,236
-55,281
-3% -$89.5K 1.03% 21
2022
Q3 		$1.92M Sell
1,788,517
-35,548
-2% -$65.3K 0.63% 32
2022
Q2 		$3.1M Sell
1,824,065
-336,825
-16% -$579K 1.09% 24
2022
Q1 		$4.45M Buy
2,160,890
+1,263,311
+141% +$3.41M 1.17% 23
2021
Q4 		$3.37M Sell
897,579
-19,909
-2% -$90.6K 0.81% 31
2021
Q3 		$4.74M Sell
917,488
-621,947
-40% -$2.79M 1.08% 25
2021
Q2 		$6.56M Buy
1,539,435
+623,724
+68% +$3.03M 1.8% 22
2021
Q1 		$4.86M Sell
915,711
-162,466
-15% -$930K 1.27% 31
2020
Q4 		$5.81M Buy
1,078,177
+503,675
+88% +$2.74M 2.1% 18
2020
Q3 		$4.58M Buy
574,502
+91,399
+19% +$800K 1.36% 26
2020
Q2 		$4.84M Buy
483,103
+323,277
+202% +$2.03M 0.27% 23
2020
Q1 		$435K Buy
+159,826
New +$530K 0.2% 48

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Endurant Capital Management's ADAP Position: Q4 2023 in Review

Endurant Capital Management sold out of Adaptimmune Therapeutics (ADAP) in Q4 2023, closing a stake of 311,944 shares — an estimated $243K sold.

Endurant Capital Management first reported a position in ADAP in Q1 2020 and held it in 15 quarters. The position peaked at $6.56M in Q2 2021. 79 funds tracked by Wall St. Rank hold ADAP as of Q4 2023.

  • Endurant Capital Management reported no remaining Adaptimmune Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Endurant Capital Management sold 311,944 Adaptimmune Therapeutics shares in Q4 2023, an estimated $243K.
  • Endurant Capital Management first reported a position in Adaptimmune Therapeutics in Q1 2020 and held it in 15 quarters.
  • Endurant Capital Management's Adaptimmune Therapeutics position peaked at $6.56M in Q2 2021.
  • 79 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2023.

Based on Endurant Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.